Highlights
- Record net business wins in the quarter of $2,378 million; a net book to bill of 1.26. Full year net business wins of $6,958 million; a net book to bill of 1.27.
- Closing backlog of $19.1 billion, an increase of 2.6% on Q3 2021 or an increase of 9.5% year over year on a Combined Company basis.
- Quarter 4 adjusted revenue of $1,881.1 million representing a year on year increase of 147.4%. Full year revenue of $5,480.8 million representing a 95.9% increase on the prior year. On a Combined Company basis, Quarter 4 adjusted revenue increased 15.1% year over year, and full year 2021 revenue increased 24.8% year over year.
- Adjusted EBITDA of $332.5 million or 17.7% of adjusted revenue, a year on year increase of 130.7%. Full year adjusted EBITDA of $970.0 million representing a year on year increase of 90.6%.
- Adjusted net income attributable to the Group was $218.0 million or $2.63 per diluted share. Full year adjusted net income attributable to the Group of $666.4 million or $9.65 per diluted share. Full year 2021 adjusted earnings per share increased 31.2% year over year.
- GAAP revenue for Quarter 4 was $1,885.1 million and for the full year was $5,480.8 million. GAAP net income attributable to the Group for Quarter 4 of $76.5 million and for the full year of $153.2 million.
- Days sales outstanding reduced to 31 days from 57 days at December 31, 2020 on a comparable basis.
- $500 million early repayment made on Term Loan B debt. Net debt balance of $4.682 billion with Net Debt to Adjusted EBITDA of 3.4x.
- Board of Directors authorized share repurchase programme up to $100 million.
- Full year 2022 revenue guidance reaffirmed in the range of $7,770 - $8,050 million, representing a year over year increase of 41.8% - 46.9%.
- Full year 2022 adjusted earnings per share guidance reaffirmed in the range of $11.55 - $11.95. Adjusted earnings per share to exclude amortization, stock compensation, foreign exchange and transaction-related / integration-related adjustments.
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today reported its financial results for the fourth quarter and full year ended December 31, 2021.
CEO Dr. Steve Cutler commented, “ICON had an outstanding year in 2021, with exceptional growth across our business as we continue to transform into the world’s largest and most comprehensive healthcare intelligence organisation. Our world class team aided in the development of 30 customer drug and device approvals in the year, including breakthrough COVID vaccines and therapies. In the first six months as the new ICON, we have already made significant progress against our initial transaction targets, with a $500m debt repayment on our Term Loan B facility, and an expectation to realize approximately 50% cost synergies by the end of 2022.
Dr. Cutler added , “We continue to see a healthy industry environment and strong customer demand, demonstrated by another record level of bookings in the fourth quarter, representing a book to bill of 1.26x, and 1.27x for the full year 2021. Additionally, a number of discussions have continued with customers contemplating an expanded or new strategic relationship with ICON, as the increased scale, innovative solutions and best in class performance of new ICON address unmet industry needs. Given this momentum entering the year, we are reaffirming our full year 2022 revenue and adjusted earnings per share guidance, representing growth of 42 – 47% in revenue and 20 – 24% in adjusted earnings per share over full year 2021.
Fourth Quarter 2021 Results
Gross business wins in the fourth quarter were $2,791 million and cancellations were $413 million. This resulted in net business wins of $2,378 million and a book to bill of 1.26.
GAAP revenue for Quarter 4 was $1,885.1 million. Adjusted revenue for Quarter 4 was $1,881.1 million. This represents a year on year increase of 147.4% or 148.7% on a constant currency basis.
GAAP net income attributable to the Group was $76.5 million. Adjusted net income attributable to the Group for the quarter was $218.0 million resulting in an adjusted diluted earnings per share of $2.63 compared to $2.10 per share for Quarter 4 2020.
Adjusted EBITDA for Quarter 4 was $332.5 million or 17.7% of revenue, a year on year increase of 130.7%.
Cash generated from operating activities for the quarter was $289.8 million. During the quarter, $47.7 million was spent on capital expenditure. At December 31, 2021, the Group had cash and cash equivalents of $752.2 million, compared to cash and cash equivalents of $1,008.5 million at September 30, 2021 and $840.3 million at the end of December 2020. During the quarter, a $500 million Term Loan B early repayment was made resulting in a net indebtedness balance of $4.682 billion at year end. Additionally, as of February 18, 2022, the Board of Directors authorized a share repurchase programme up to $100 million to opportunistically buy back shares.
Full Year 2021 Results
Gross business wins were $8,121 million and cancellations were $1,163 million. This resulted in net business wins of $6,958 million and a book to bill of 1.27.
Full year revenue was $5,480.8 million. This represents a year on year increase of 95.9% or 94.5% on a constant currency basis.
GAAP net income attributable to the Group was $153.2 million. Adjusted net income attributable to the Group was $666.4 million resulting in an adjusted diluted earnings per share of $9.65 compared to $7.36 per share for the equivalent prior year period.
Adjusted EBITDA was $970.0 million or 17.7% of revenue, a year on year increase of 90.6%.
Other Information
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including adjusted revenue, adjusted EBITDA, adjusted net income attributable to the Group and adjusted diluted earnings per share attributable to the Group. Adjusted EBITDA, adjusted net income and adjusted diluted earnings per share exclude amortization, stock compensation, foreign exchange gains and losses and transaction-related / integration-related adjustments. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.
To assist investors and analysts with year-over-year comparability for the merged business, we have included Combined Company information. These measures include financial information that combines the stand-alone ICON plc and PRA Health Sciences, Inc. information for revenue and Adjusted EBITDA, and other metrics as if the merger had taken place on January 1, 2020, with conforming adjustments to the current year presentation. Specifically, these financials represent the simple addition of the historical adjusted financials of each company. These combined financials are not intended to represent pro forma financial statements prepared in accordance with GAAP or Regulation S-X.
For the year ended 31 December 2020, GAAP earnings per share attributable to the Group has been computed by dividing net income attributable to the Group plus a GAAP charge associated with non-controlling interest in MeDiNova Research (“MeDiNova”) by the weighted average number of shares outstanding. ICON purchased a majority shareholding in MeDiNova on May 23, 2019. ICON exercised its call on the outstanding shares in MeDiNova and derecognised the non-controlling interest effective from March 2020.
ICON will hold a conference call today, February 22nd, 2022 at 09:00 EST [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under “Investors”. This calendar will be updated regularly.
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http://www.sec.gov.
Our full-year 2022 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. Such items include, but are not limited to, transaction-related / integration-related expenses, restructuring and related expenses, and other items not reflective of the company's ongoing operations.
ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 38,330 employees in 142 locations in 53 countries as at December 31, 2021. For further information about ICON, visit: www.iconplc.com.
Source: ICON plc
ICON/ICLR-F
ICON plc |
||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||
FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2021 AND DECEMBER 31, 2020
|
||||||||||||||||
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||
|
|
December 31,
|
|
December 31,
|
|
December 31,
|
|
December 31,
|
||||||||
|
(in thousands except share and per share data) |
|||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
Revenue |
|
$ |
1,885,121 |
|
|
$ |
760,229 |
|
|
$ |
5,480,826 |
|
|
$ |
2,797,288 |
|
|
|
|
|
|
|
|
|
|
||||||||
Costs and expenses: |
|
|
|
|
|
|
|
|
||||||||
Direct costs (excluding depreciation and amortization) |
|
1,357,303 |
|
|
535,347 |
|
|
3,972,612 |
|
|
1,979,883 |
|
||||
Selling, general and administrative expense |
|
202,716 |
|
|
88,140 |
|
|
585,330 |
|
|
342,449 |
|
||||
Depreciation and amortization |
|
139,670 |
|
|
17,145 |
|
|
314,987 |
|
|
66,126 |
|
||||
Transaction and integration-related expenses (credit) |
|
15,954 |
|
|
(262 |
) |
|
198,263 |
|
|
(759 |
) |
||||
Restructuring |
|
24,943 |
|
|
— |
|
|
31,105 |
|
|
18,089 |
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Total costs and expenses |
|
1,740,586 |
|
|
640,370 |
|
|
5,102,297 |
|
|
2,405,788 |
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Income from operations |
|
144,535 |
|
|
119,859 |
|
|
378,529 |
|
|
391,500 |
|
||||
Interest income |
|
78 |
|
|
206 |
|
|
574 |
|
|
2,724 |
|
||||
Interest expense |
|
(52,839 |
) |
|
(3,379 |
) |
|
(182,423 |
) |
|
(13,019 |
) |
||||
|
|
|
|
|
|
|
|
|
||||||||
Income before provision for income taxes |
|
91,774 |
|
|
116,686 |
|
|
196,680 |
|
|
381,205 |
|
||||
Provision for income taxes |
|
(14,616 |
) |
|
(15,169 |
) |
|
(41,334 |
) |
|
(47,875 |
) |
||||
|
|
|
|
|
|
|
|
|
||||||||
Income before share of earnings from equity method |
|
77,158 |
|
|
101,517 |
|
|
155,346 |
|
|
333,330 |
|
||||
Share of equity method investments |
|
(690 |
) |
|
(283 |
) |
|
(2,161 |
) |
|
(366 |
) |
||||
|
|
|
|
|
|
|
|
|
||||||||
Net income |
|
76,468 |
|
|
101,234 |
|
|
153,185 |
|
|
332,964 |
|
||||
Net income attributable to noncontrolling interest |
|
— |
|
|
— |
|
|
— |
|
|
(633 |
) |
||||
Net income attributable to the Group |
|
$ |
76,468 |
|
|
$ |
101,234 |
|
|
$ |
153,185 |
|
|
$ |
332,331 |
|
|
|
|
|
|
|
|
|
|
||||||||
Net income per Ordinary Share attributable to the Group: |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Basic |
|
$ |
0.94 |
|
|
$ |
1.92 |
|
|
$ |
2.28 |
|
|
$ |
6.20 |
|
Diluted |
|
$ |
0.92 |
|
|
$ |
1.90 |
|
|
$ |
2.25 |
|
|
$ |
6.15 |
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted average number of Ordinary Shares outstanding: |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Basic |
|
81,488,189 |
|
|
52,783,886 |
|
|
67,110,186 |
|
|
52,859,911 |
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Diluted |
|
82,827,674 |
|
|
53,291,849 |
|
|
68,068,311 |
|
|
53,283,585 |
|
||||
ICON plc |
|||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||||
AS AT DECEMBER 31, 2021 AND DECEMBER 31, 2020
|
|||||||
|
|
|
|
||||
|
December 31,
|
|
December 31,
|
||||
ASSETS |
(in thousands) |
||||||
Current Assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
752,213 |
|
|
$ |
840,305 |
|
Available for sale investments |
1,712 |
|
|
1,729 |
|
||
Accounts receivable, net of allowance for credit losses |
1,342,770 |
|
|
715,271 |
|
||
Unbilled revenue |
623,121 |
|
|
428,684 |
|
||
Other receivables |
56,760 |
|
|
35,394 |
|
||
Prepayments and other current assets |
114,323 |
|
|
53,477 |
|
||
Income taxes receivable |
50,299 |
|
|
28,118 |
|
||
Total current assets |
2,941,198 |
|
|
2,102,978 |
|
||
|
|
|
|
||||
Other Assets: |
|
|
|
||||
Property, plant and equipment, net |
336,444 |
|
|
174,343 |
|
||
Goodwill |
9,037,931 |
|
|
936,257 |
|
||
Operating right-of-use assets |
198,123 |
|
|
84,561 |
|
||
Other non-current assets |
70,557 |
|
|
20,773 |
|
||
Non-current income taxes receivable |
18,637 |
|
|
17,230 |
|
||
Deferred tax asset |
48,392 |
|
|
12,705 |
|
||
Equity method investments |
2,373 |
|
|
4,534 |
|
||
Investments in equity-long term |
22,592 |
|
|
15,765 |
|
||
Intangible assets |
4,710,843 |
|
|
66,460 |
|
||
Total Assets |
$ |
17,387,090 |
|
|
$ |
3,435,606 |
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
||||
Current Liabilities: |
|
|
|
||||
Accounts payable |
$ |
90,764 |
|
|
$ |
51,113 |
|
Unearned revenue |
1,323,961 |
|
|
660,883 |
|
||
Other liabilities |
949,629 |
|
|
399,769 |
|
||
Income taxes payable |
59,433 |
|
|
12,178 |
|
||
Current bank credit lines and loan facilities |
55,150 |
|
|
— |
|
||
Total current liabilities |
2,478,937 |
|
|
1,123,943 |
|
||
Other Liabilities: |
|
|
|
||||
Non-current bank credit lines and loan facilities |
5,381,162 |
|
|
348,477 |
|
||
Non-current operating lease liabilities |
159,483 |
|
|
60,801 |
|
||
Non-current other liabilities |
41,861 |
|
|
26,366 |
|
||
Non-current government grants |
735 |
|
|
838 |
|
||
Non-current income taxes payable |
172,109 |
|
|
14,539 |
|
||
Non-current deferred tax liability |
1,085,976 |
|
|
10,406 |
|
||
Commitments and contingencies |
— |
|
|
— |
|
||
Total Liabilities |
9,320,263 |
|
|
1,585,370 |
|
||
|
|
|
|
||||
Shareholders' Equity: |
|
|
|
||||
Ordinary shares, par value 6 euro cents per share; 100,000,000 shares authorised, |
|
|
|
||||
81,554,683 shares issued and outstanding at December 31, 2021 and |
|
|
|
||||
52,788,093 shares issued and outstanding at December 31, 2020 |
6,640 |
|
|
4,580 |
|
||
Additional paid-in capital |
6,733,910 |
|
|
617,104 |
|
||
Other undenominated capital |
1,134 |
|
|
1,134 |
|
||
Accumulated other comprehensive loss |
(90,937 |
) |
|
(35,477 |
) |
||
Retained earnings |
1,416,080 |
|
|
1,262,895 |
|
||
Total Shareholders' Equity |
8,066,827 |
|
|
1,850,236 |
|
||
Total Liabilities and Shareholders' Equity |
$ |
17,387,090 |
|
|
$ |
3,435,606 |
|
ICON plc |
|||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||
FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2021 AND DECEMBER 31, 2020
|
|||||||
|
|
||||||
|
Twelve Months Ended |
||||||
|
December 31,
|
|
December 31,
|
||||
|
(in thousands) |
||||||
Cash flows from operating activities: |
|
|
|
||||
Net income |
$ |
153,185 |
|
|
$ |
332,964 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
||||
Depreciation and amortization expense |
314,987 |
|
|
66,126 |
|
||
Impairment of long lived assets |
20,037 |
|
|
5,411 |
|
||
Reduction in carrying value of operating right-of-use assets |
45,339 |
|
|
28,480 |
|
||
Unrealised foreign exchange (gain)/loss |
(6,054 |
) |
|
5,979 |
|
||
Loss on extinguishment of debt |
73,894 |
|
|
— |
|
||
Loss on equity method investments |
2,161 |
|
|
366 |
|
||
Stock compensation expense |
133,844 |
|
|
26,271 |
|
||
Charge/(credit) on interest rate hedge |
891 |
|
|
(910 |
) |
||
Amortization of financing costs |
12,890 |
|
|
523 |
|
||
Deferred tax (benefit)/expense |
(60,616 |
) |
|
927 |
|
||
Other non-cash items |
3,589 |
|
|
(6,949 |
) |
||
Changes in operating assets and liabilities, net of acquired assets and assumed liabilities: |
|
|
|
||||
Accounts receivable |
113,513 |
|
|
(175,040 |
) |
||
Unbilled revenue |
(17,656 |
) |
|
(5,748 |
) |
||
Unearned revenue |
(69,121 |
) |
|
291,844 |
|
||
Other net assets |
108,259 |
|
|
(2,209 |
) |
||
Net cash provided by operating activities |
829,142 |
|
|
568,035 |
|
||
Cash flows from investing activities: |
|
|
|
||||
Purchase of property, plant and equipment |
(93,750 |
) |
|
(40,885 |
) |
||
Purchase of subsidiary undertakings |
(5,914,475 |
) |
|
(47,931 |
) |
||
Investment in equity method investments |
(2,450 |
) |
|
(2,450 |
) |
||
Loan to equity method investment |
(10,000 |
) |
|
— |
|
||
Sale of available for sale investments |
497 |
|
|
47,902 |
|
||
Purchase of available for sale investments |
(480 |
) |
|
— |
|
||
Purchase of investments in equity - long term |
(3,577 |
) |
|
(3,212 |
) |
||
Net cash used in investing activities |
(6,024,235 |
) |
|
(46,576 |
) |
||
Cash flows from financing activities: |
|
|
|
||||
Financing costs |
(30,328 |
) |
|
(1,554 |
) |
||
Drawdown of credit lines and facilities |
5,905,100 |
|
|
350,000 |
|
||
Repayment of credit lines and facilities |
(877,780 |
) |
|
(350,000 |
) |
||
Purchase of noncontrolling interest |
— |
|
|
(43,923 |
) |
||
Proceeds from exercise of equity compensation |
118,589 |
|
|
13,203 |
|
||
Share issue costs |
(853 |
) |
|
(14 |
) |
||
Repurchase of ordinary shares |
— |
|
|
(175,000 |
) |
||
Share repurchase costs |
— |
|
|
(140 |
) |
||
Settlement of interest rate hedge |
— |
|
|
(905 |
) |
||
Net cash provided by (used in) financing activities |
5,114,728 |
|
|
(208,333 |
) |
||
Effect of exchange rate movements on cash |
(7,727 |
) |
|
6,870 |
|
||
Net (decrease) increase in cash and cash equivalents |
(88,092 |
) |
|
319,996 |
|
||
Cash and cash equivalents at beginning of year |
840,305 |
|
|
520,309 |
|
||
Cash and cash equivalents at end of year |
$ |
752,213 |
|
|
$ |
840,305 |
|
ICON plc |
||||||||||||||||
RECONCILIATION OF NON-GAAP MEASURES |
||||||||||||||||
FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2021 AND DECEMBER 31, 2020 |
||||||||||||||||
(UNAUDITED) |
||||||||||||||||
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||
|
|
December
|
|
December
|
|
December
|
|
December
|
||||||||
|
|
(in thousands except share and per share data) |
||||||||||||||
|
|
|
|
|
|
|
||||||||||
Adjusted revenue |
|
|
|
|
|
|||||||||||
Revenue, as reported |
$ |
1,885,121 |
|
|
$ |
760,229 |
|
|
$ |
5,480,826 |
|
$ |
2,797,288 |
|
||
Acquisition related deferred revenue adjustment (a) |
|
|
(4,000 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Adjusted revenue |
|
$ |
1,881,121 |
|
|
$ |
760,229 |
|
|
$ |
5,480,826 |
|
|
$ |
2,797,288 |
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA |
|
|
|
|
|
|
|
|
||||||||
Net income attributable to the Group |
$ |
76,468 |
|
|
$ |
101,234 |
|
|
$ |
153,185 |
|
|
$ |
332,331 |
|
|
Net income attributable to non-controlling interest |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
633 |
|
Share of equity method investments |
|
|
690 |
|
|
|
283 |
|
|
|
2,161 |
|
|
|
366 |
|
Provision for income taxes |
|
|
14,616 |
|
|
|
15,169 |
|
|
|
41,334 |
|
|
|
47,875 |
|
Net interest expense (b) |
|
|
52,761 |
|
|
|
3,173 |
|
|
|
181,849 |
|
|
|
10,295 |
|
Depreciation and amortization |
|
|
139,670 |
|
|
|
17,145 |
|
|
|
314,987 |
|
|
|
66,126 |
|
Stock-based compensation expense (c) |
|
|
19,410 |
|
|
|
6,402 |
|
|
|
61,397 |
|
|
|
27,833 |
|
Foreign currency losses (gains), net (d) |
|
|
(7,968 |
) |
|
|
1,001 |
|
|
|
(14,314 |
) |
|
|
5,979 |
|
Restructuring (e) |
|
|
24,943 |
|
|
|
— |
|
|
|
31,105 |
|
|
|
18,089 |
|
Acquisition related deferred revenue adjustment (a) |
|
|
(4,000 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Transaction-related / integration-related costs (f) |
|
|
15,954 |
|
|
|
(262 |
) |
|
|
198,263 |
|
|
|
(759 |
) |
Adjusted EBITDA |
|
$ |
332,544 |
|
|
$ |
144,145 |
|
|
$ |
969,967 |
|
|
$ |
508,768 |
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted net income attributable to the Group and adjusted diluted net income per Ordinary Share attributable to the Group |
|
|
|
|
|
|
|
|
||||||||
Net income attributable to the Group |
$ |
76,468 |
|
|
$ |
101,234 |
|
|
$ |
153,185 |
|
|
$ |
332,331 |
|
|
Provision for income taxes |
|
|
14,616 |
|
|
|
15,169 |
|
|
|
41,334 |
|
|
|
47,875 |
|
Amortisation |
|
|
114,888 |
|
|
|
4,806 |
|
|
|
239,503 |
|
|
|
19,234 |
|
Stock-based compensation expense (c) |
|
|
19,410 |
|
|
|
6,402 |
|
|
|
61,397 |
|
|
|
27,833 |
|
Foreign currency losses (gains), net (d) |
|
|
(7,968 |
) |
|
|
1,001 |
|
|
|
(14,314 |
) |
|
|
5,979 |
|
Restructuring (e) |
|
|
24,943 |
|
|
|
— |
|
|
|
31,105 |
|
|
|
18,089 |
|
Acquisition related deferred revenue adjustment (a) |
|
|
(4,000 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Transaction-related / integration-related costs (f) |
|
|
15,954 |
|
|
|
(262 |
) |
|
|
198,263 |
|
|
|
(759 |
) |
Transaction-related financing costs (g) |
|
|
8,484 |
|
|
|
— |
|
|
|
86,736 |
|
|
|
— |
|
Adjusted tax expense (h) |
|
|
(44,798 |
) |
|
|
(16,675 |
) |
|
|
(130,791 |
) |
|
|
(58,500 |
) |
Adjusted net income attributable to the Group |
|
$ |
217,997 |
|
|
$ |
111,675 |
|
|
$ |
666,419 |
|
|
$ |
392,082 |
|
|
|
|
|
|
|
|
|
|
||||||||
Diluted weighted average number of Ordinary Shares outstanding |
|
|
82,827,674 |
|
|
|
53,291,849 |
|
|
|
|
|
53,283,585 |
|
||
|
|
|
|
|
|
|
|
|
||||||||
Adjusted diluted net income per Ordinary Share attributable to the Group (i) |
|
$ |
2.63 |
|
|
$ |
2.10 |
|
|
$ |
9.65 |
|
|
$ |
7.36 |
|
ICON plc |
|||||||||||||||
RECONCILIATION OF NON-GAAP MEASURES (COMBINED COMPANY) |
|||||||||||||||
FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2021 AND DECEMBER 31, 2020 |
|||||||||||||||
(UNAUDITED) |
|||||||||||||||
|
|
|
|
|
|||||||||||
|
|
Three Months Ended |
|
Twelve Months Ended |
|||||||||||
|
|
December
|
|
December
|
|
December
|
|
December
|
|||||||
|
|
(in thousands except share and per share data) |
|||||||||||||
|
|
|
|
|
|
|
|||||||||
Combined Company adjusted revenue |
|
|
|
|
|
||||||||||
Revenue, as reported |
$ |
1,885,121 |
|
|
$ |
760,229 |
|
$ |
5,480,826 |
|
|
$ |
2,797,288 |
|
|
Pre-merger PRA Health Sciences Revenue |
|
— |
|
|
|
873,458 |
|
|
1,981,173 |
|
|
|
3,183,365 |
|
|
Combined Company Revenue, before adjustments |
|
1,885,121 |
|
|
|
1,633,687 |
|
|
7,461,999 |
|
|
|
5,980,653 |
|
|
Acquisition related deferred revenue adjustment (a) |
|
|
(4,000 |
) |
|
|
— |
|
|
— |
|
|
|
— |
|
Combined Company adjusted revenue |
|
$ |
1,881,121 |
|
|
$ |
1,633,687 |
|
$ |
7,461,999 |
|
|
$ |
5,980,653 |
|
|
|
|
|
|
|
|
|
|
|||||||
Combined Company adjusted EBITDA |
|
|
|
|
|
|
|
|
|||||||
Net income attributable to the Group |
$ |
76,468 |
|
|
$ |
101,234 |
|
$ |
153,185 |
|
|
$ |
332,331 |
|
|
Pre-merger PRA Health Sciences Net income attributable to the Group |
|
— |
|
|
|
51,257 |
|
|
128,008 |
|
|
|
197,043 |
|
|
Combined Company Net income attributable to the Group |
|
76,468 |
|
|
|
152,491 |
|
|
281,194 |
|
|
|
529,374 |
|
|
Net income attributable to non-controlling interest |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
633 |
|
Share of equity method investments |
|
|
690 |
|
|
|
283 |
|
|
2,161 |
|
|
|
366 |
|
Provision for income taxes |
|
|
14,616 |
|
|
|
40,094 |
|
|
48,034 |
|
|
|
109,841 |
|
Net interest expense (b) |
|
|
52,761 |
|
|
|
10,651 |
|
|
191,740 |
|
|
|
53,875 |
|
Depreciation and amortization |
|
|
139,670 |
|
|
|
50,697 |
|
|
380,730 |
|
|
|
197,756 |
|
Stock-based compensation expense (c) |
|
|
19,410 |
|
|
|
25,202 |
|
|
98,901 |
|
|
|
97,246 |
|
Foreign currency losses (gains), net (d) |
|
|
(7,968 |
) |
|
|
14,464 |
|
|
(20,586 |
) |
|
|
31,478 |
|
Restructuring (e) |
|
|
24,943 |
|
|
|
— |
|
|
31,105 |
|
|
|
18,089 |
|
Acquisition related deferred revenue adjustment (a) |
|
|
(4,000 |
) |
|
|
— |
|
|
— |
|
|
|
— |
|
Transaction-related / integration-related costs (f) |
|
|
15,954 |
|
|
|
1,167 |
|
|
235,115 |
|
|
|
(42,219 |
) |
Combined Company adjusted EBITDA |
|
$ |
332,545 |
|
|
$ |
295,049 |
|
$ |
1,248,394 |
|
|
$ |
996,439 |
|
| (a) | In Q3 2021, an acquisition related deferred revenue adjustment was reflected representing non-cash adjustments resulting from the revaluation of deferred revenue and the subsequent charge to revenue in connection with business combinations. In Q4 2021, the charge to revenue was reversed as the company has taken the option to early adopt amendments to the relevant accounting standard. |
| (b) | Net interest expense includes losses on modification or extinguishment of debt. |
| (c) | Stock-based compensation expense represents the amount of recurring non-cash expense related to the Company’s equity compensation programs (inclusive of employer related taxes). |
| (d) | Foreign currency losses (gains), net relates to gains or losses that arise in connection with the revaluation of non-US dollar denominated assets and liabilities. We exclude these gains and losses from adjusted EBITDA and adjusted net income because fluctuations from period- to- period do not necessarily correspond to changes in our operating results. |
| (e) | Restructuring charges incurred relate to charges incurred in connection with the termination of leases at locations that are no longer being used and amounts incurred in connection with the elimination of redundant positions within the organisation. |
| (f) | Transaction-related / integration-related costs include expenses/credits associated with our acquisitions, share-based compensation expense related to the acceleration of share-based compensation awards and replacement share-based awards, contingent consideration valuation adjustments, and any other costs incurred directly related to the integration of these acquisitions. |
| (g) | Transaction-related financing costs includes costs incurred in connection with changes to our long-term debt and amortization of financing fees. We exclude these costs from Adjusted EBITDA and Adjusted Net Income because they result from financing decisions rather than from decisions made related to our ongoing operations. |
| (h) | Represents the tax effect of adjusted pre-tax income at our estimated effective tax rate. |
| (i) | Earnings per share for FY 2021 reflects sum of earnings per share for the four quarters of 2021. FY 2021 EPS calculated using the diluted weighted average number of Ordinary Shares in 2021 would be higher at $9.79. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005411/en/
Contacts
Investor Relations +1888 381 7923 or
Brendan Brennan Chief Financial Officer +353 1 291 2000
Kate Haven Vice President Investor Relations +1888 381 7923
All at ICON.
http://www.iconplc.com
